©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Regulated Formation of Golgi Secretory Vesicles Containing Alzheimer -Amyloid Precursor Protein (*)

(Received for publication, July 3, 1995)

Huaxi Xu (1) (2) Paul Greengard (2) Sam Gandy (1)(§)

From the  (1)Laboratory of Alzheimer Research, Department of Neurology and Neuroscience, Cornell University Medical College, New York, New York 10021 and (2)Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Phorbol esters, activators of protein kinase C (PKC), regulate the relative utilization of alternative processing pathways for the Alzheimer beta-amyloid precursor protein (beta-APP) in intact cells, increasing the production of nonamyloidogenic soluble beta-APP (sbeta-APP) and decreasing that of neurotoxic beta-amyloid (Abeta) peptide. The molecular and cellular bases of PKC-regulated beta-APP cleavage are poorly understood. Here we demonstrate in a reconstituted cell-free system that activation of endogenous PKC increases formation from the trans-Golgi network of secretory vesicles containing beta-APP and that this effect can be mimicked by purified PKC. The results demonstrate directly that PKC is involved in regulation of secretory vesicle formation and provide a mechanism by which PKC may reduce the formation of the Abeta peptide characteristic of Alzheimer disease.


INTRODUCTION

Alzheimer disease (AD) (^1)is a common neurodegenerative disorder characterized by dementia and by accumulation in the brain of extracellular deposits composed of beta-amyloid peptide (Abeta) (Glenner and Wong, 1984). Signal transduction via protein phosphorylation governs the relative utilization of competing pathways for the metabolism of the beta-amyloid precursor protein (beta-APP) (Kang et al., 1987), the type 1 integral glycoprotein from which Abeta is derived by proteolytic processing. Activated protein kinase C (PKC) stimulates nonamyloidogenic beta-APP cleavage (Buxbaum et al., 1990; Caporaso et al., 1992), generating soluble beta-APP (sbeta-APP) at the expense of other pathways, including that involved in the formation of Abeta (Hung et al., 1993). PKC-regulated beta-APP cleavage does not require changes in the phosphorylation state of the beta-APP cytoplasmic tail (da Cruz e Silva et al., 1993), suggesting that one or more molecules of the beta-APP trafficking and processing apparatus are PKC substrate phosphoproteins involved in the mechanism by which PKC regulates beta-APP cleavage.

Most beta-APP resides intracellularly, codistributing with TGN38, a marker of the trans-Golgi network (TGN) (Caporaso et al., 1994). Thus, it seemed possible that PKC might exert its actions on regulated beta-APP cleavage by redistributing beta-APP out of its usual residence in the TGN and toward post-TGN compartments where it can undergo processing. This possibility is supported by studies demonstrating stimulation by phorbol esters of the release of glycosaminoglycans, intraluminal molecules of the constitutive secretory pathway (De Matteis et al., 1993; Ohashi and Huttner, 1994). Therefore, we have tested the possibility that an important component of regulated beta-APP cleavage is PKC-stimulated formation from TGN of constitutive secretory vesicles containing and transporting mature beta-APP.


MATERIALS AND METHODS

Intact Cell Studies

Three plates of PC12 cells (10-cm dishes, 5 times 10^7 cells/dish) were labeled with 2 mCi/ml [S]sulfate (Amersham Corp.) for 10 min and chased at 37 °C in the presence or absence of 1 µM PDBu (LC Services, Woburn, MA) for 5, 15, or 45 min. At the end of the incubation, media were collected and immunoprecipitated with beta-APP amino-terminal antibody 22C11 (Caporaso et al., 1992). Cells were homogenized, and Golgi-rich membrane fractions were prepared by flotation using a stepwise sucrose gradient (Xu and Shields, 1993). The Golgi-rich fractions were immunoprecipitated with beta-APP carboxyl-terminal antibody 369 (Buxbaum et al., 1990). Immunoprecipitates were resuspended in 1% SDS and adjusted to equal amounts of total protein (Bradford), followed by 4-12% SDS-polyacrylamide gel electrophoresis analysis and autoradiography on Kodak X-Omat AR5 film.

Cell-free Vesicle Budding Assay

Confluent PC12 cells (5 times 10^7) were pulse-labeled with 2 mCi/ml [S]sulfate (Amersham Corp.) for 5 min in sulfate-free medium (Life Technologies, Inc.) at 37 °C. Cells from each 10-cm dish were homogenized using a stainless steel ball bearing homogenizer (18-µm clearance) in 5 volumes of homogenization buffer (0.25 M sucrose, 1 mM magnesium acetate, 0.5 mM EDTA, 0.2 mM CaCl(2), and proteinase inhibitors) (Xu and Shields, 1993). A postnuclear supernatant was prepared (Tooze and Huttner, 1992) and centrifuged (Beckman TLA-45 rotor) at 14,000 times g for 10 min at 4 °C. The pellet was then washed and resuspended in 300 µl of homogenization buffer. Aliquots (100 µl of membrane preparation) of resulting suspension, the ``TGN-rich fraction,'' were incubated in a final volume of 250 µl at 37 °C for 30 min in the presence of an energy-regenerating system containing 1 mM ATP and 0.2 mM GTP in the absence or presence of 1 mg of cytosol protein/ml (Xu and Shields, 1993). At the end of the incubation period, samples were centrifuged (Beckman TLA-45 rotor) at 14,000 times g for 10 min at 4 °C. The pellets and supernatants were separated and immunoprecipitated with antibody 369 and subjected to SDS-polyacrylamide gel electrophoresis and autoradiography. (^2)The redistribution of S-sulfated beta-APP into the supernatant provides a measure of budding of vesicles containing beta-APP. Treatment of the vesicle-containing supernatant with proteinase K (25 µg/ml, Boehringer Mannheim) resulted in disappearance of the beta-APP-like 22C11 (ectodomain)-immunoreactive material in the presence, but not in the absence, of 1% Triton X-100, consistent with the predicted existence of the beta-APP ectodomain within a vesicular lumen (data not shown).

Quantification and pairwise analyses were carried out using a Bio-Rad phosphor imaging system (Molecular Analyst version 2.0 software). For each experiment, the level of budding observed in the presence of an aliquot of a standard preparation of cytosol was taken as 1 arbitrary unit of budding efficiency, and other levels within a given experiment were normalized to this value.

Modulation of Vesicle Budding in the Cell-free Assay

In some experiments, modulation of vesicle budding was tested using (together and separately) purified rat brain PKC (Woodgett and Hunter, 1987) and/or PKC inhibitor peptide-(19-36) (House and Kemp, 1987). PKC inhibitor peptide-(19-36), used at 200 µM as recommended (House and Kemp, 1987), was synthesized at the Keck Foundation Protein Synthesis and Sequencing Facility at Yale University, New Haven, CT. Effects on vesicle budding were also tested for GTPS (30 µM) (Boehringer Mannheim) or (AlF(4)) (80 µM Al plus 6 mM F).

Stripping of Golgi-rich Membranes Prior to Use in the Cell-free Vesicle Budding Assay

In some experiments, TGN-rich fractions derived from [S]sulfate-labeled cells were washed with low (control) or high salt and analyzed for vesicle budding in the absence or presence of PDBu (1 µM)/purified PKC (25 µg/ml) or cytosol (1 mg/ml). For washing of membrane preparations, the [S]sulfate-labeled TGN-rich fractions were adjusted to 100 or 400 mM potassium acetate and incubated at 4 °C for 10 min followed by 10 min of centrifugation (Beckman TLA-45 rotor) at 14,000 times g at 4 °C. The pellets were then washed in homogenization buffer, resuspended in buffer of the same composition, and used in the cell-free vesicle budding assay.


RESULTS AND DISCUSSION

Golgi-rich Fractions from Phorbol Ester-treated Cells Are Depleted of beta-APP

In intact cells, PDBu caused a depletion of Golgi-associated mature, sulfated beta-APP (Fig. 1). Sulfated beta-APP holoprotein content of the Golgi-rich fraction (Xu and Shields, 1993) from metabolically labeled cells chased in the presence of PDBu for 5 or 15 min was approximately 30 and 40%, respectively, of that observed in the absence of PDBu (Fig. 1, leftpanel). Concomitantly, appearance of sbeta-APP in the medium was enhanced severalfold at all times studied (Fig. 1, rightpanel).


Figure 1: PKC activation in intact PC12 cells leads to redistribution of holo-beta-APP from a Golgi-rich fraction to sbeta-APP in conditioned culture medium. Cells were metabolically labeled with [S]sulfate, followed by analysis of beta-APP in a Golgi-rich membrane fraction from the cells and of sbeta-APP in the culture medium. The autoradiograms are from one of two experiments, which yielded virtually identical results.



PKC Activation Stimulates TGN Vesicle Formation in a Cell-free System

Regulation by protein phosphorylation of the biogenesis of beta-APP-containing vesicles was directly demonstrated using a modification of an in vitro assay of secretory vesicle formation from a TGN-rich fraction (Ohashi and Huttner, 1994). This assay allows study of the effects of cell-impermeant agents such as PKC and GTPS. Since it is well established that several cytosolic molecules play important roles in vesicle budding (for review, see Rothman(1994)), budding from isolated TGN was tested in the absence and presence of cytosol.

Cytosol stimulated the formation of nascent vesicles containing beta-APP (Fig. 2, autoradiogram, lane1versuslane 6; Fig. 3A, lane1versuslane 2). This stimulatory effect was mimicked by purified PKC (Woodgett and Hunter, 1987), with a half-maximal effect at 9 µg/ml and a maximal effect at 25 µg/ml (Fig. 2, graph; Fig. 3A, lane1versuslane 6). In the presence of cytosol, the addition of PDBu increased vesicle budding, presumably due to activation of endogenous PKC (Fig. 3A, lane2versuslane5). The rate of vesicle budding observed in the presence of cytosol alone or of cytosol plus PDBu/PKC was greatly reduced in the presence of PKC inhibitor peptide-(19-36) (House and Kemp, 1987) (Fig. 3A, lane2versuslane 3, lane 7versuslane 8). Cytosol caused a significant increase in vesicle budding from the TGN even in the presence of an optimally effective amount of PDBu/PKC (Fig. 3A, lane6versuslane7), suggesting the presence of a cytosolic factor(s) in addition to PKC. A similar additional stimulatory effect of cytosol was observed when cytosol was added to stripped Golgi membranes (see below) in the presence of optimally effective PDBu/PKC (not shown). The effect of cytosol alone was abolished in the absence of an energy-regenerating system or when incubation was carried out at 20 °C, a temperature that blocks TGN exit (Fig. 3B).


Figure 2: Stimulation of vesicle budding from TGN by cytosol and by purified PKC. A TGN-rich fraction derived from [S]sulfate-labeled cells was incubated under standard conditions in the presence of cytosol or of various concentrations of purified PKC followed by analysis of vesicle budding (see ``Materials and Methods'').




Figure 3: Regulation of vesicle budding from TGN. A, effect of cytosol (1 mg/ml), PDBu (1 µM), PKC (25 µg/ml), and PKC inhibitor peptide-(19-36) (200 µM) on vesicle budding. B, reduction of vesicle budding by removal of energy regenerating system (-ERS), incubation at 20 °C, or addition of either GTPS (30 µM) or (AlF(4)) (80 µM Al plus 6 mM F). Means ± S.E. for three experiments are shown. asterisk, different from cytosol alone (p < 0.01); dagger, different from PDBu/PKC alone (p < 0.01).



GTPS and Aluminum Fluoride Inhibit TGN Vesicle Formation in a Cell-free System

Vesicle budding is known to be dynamically regulated (see Bauerfeind and Huttner(1993) for review). Numerous reports have implicated GTP binding proteins (both the small Ras-like class and the heterotrimeric class) in many processes of intracellular vesicular transport including formation of secretory vesicles from the TGN. (AlF(4)), an activator of both stimulatory and inhibitory trimeric G proteins, diminished the budding of secretory vesicles containing beta-APP, indicating the involvement of heterotrimeric G proteins. Consistent with this interpretation, GTPS, a non-hydrolyzable GTP analogue, also reduced budding (Fig. 3B).

Activated Purified PKC Stimulates Vesicle Budding from Stripped Golgi Membranes, Suggesting That Budding Is Regulated by a Tightly Associated or Integral TGN Phosphoprotein

In order to investigate whether the PKC substrate that regulated budding was likely to be cytosolic or TGN-associated, the [S]sulfate-labeled, TGN-rich fraction was washed with 100 mM (control) or 400 mM (high salt) potassium acetate. Control and high salt-washed TGN were then assayed for vesicle formation in the absence or presence of purified PKC or cytosol (Fig. 4). The ability of PKC to stimulate vesicle budding in the absence of cytosol was largely retained after stripping of the TGN with high salt. The results suggest that at least one important PKC target is likely to be a tightly associated cytosolic or integral TGN phosphoprotein, presumably acting downstream from various known components of the budding apparatus (Rothman, 1994).


Figure 4: PKC stimulates vesicle budding from washed TGN-rich membranes. TGN fractions derived from [S]sulfate-labeled cells were washed with low (control) or high salt and analyzed for vesicle budding in the absence or presence of PDBu (1 µM)/purified PKC (25 µg/ml) or cytosol (1 mg/ml).



Conclusions

The present results demonstrate that when appropriate PKC-mediated signal transduction systems are activated, beta-APP is redistributed from the TGN to other cellular locations where it can encounter its processing enzymes, e.g. to the plasma membrane, where it is cleaved by ``alpha-secretase,'' another candidate PKC target (Bosenberg et al., 1993; Arribas and Massague, 1995). The data also support the idea that the so-called ``constitutive'' secretory pathway is subjected to important regulatory influences and that some of this regulation occurs via protein phosphorylation/dephosphorylation (De Matteis et al., 1993; Ohashi and Huttner, 1994). Our results indicate that PKC constitutes an important component of the contribution of cytosol to the regulation of budding. Moreover, the evidence suggests that at least one important PKC substrate is tightly associated with the TGN.

In Alzheimer patients of the Swedish familial AD type, there is an abnormally low ratio of processing of beta-APP via the non-amyloidogenic sbeta-APP pathway relative to the amyloidogenic Abeta pathway (Felsenstein et al., 1994a). This ratio is normalized by activation of PKC, which enhances processing via the non-amyloidogenic pathway while decreasing processing via the amyloidogenic pathway (Felsenstein et al., 1994b; Citron et al., 1994). The present study reveals one cellular mechanism by which PKC produces these effects. In addition, the recent discovery that a major familial AD gene (Sherrington et al., 1995) encodes a protein homologous to the Caenorhabditis elegans sperm molecule spe4, which plays a role in membrane protein sorting (L'Hernault and Arduengo, 1992), raises the possibility that missorting of beta-APP may contribute to some forms of AD. A more complete understanding of the molecules that control beta-APP trafficking and processing events, as well as an understanding of how these molecules are regulated, should lead to new insights into the etiology, pathogenesis, and therapy of AD.


FOOTNOTES

*
This work was supported by The C. V. Starr Foundation (to S. G.), a Cornell Scholar Award in the Biomedical Sciences (to S. G.), and United States Public Health Service Grants AG09464 (to P. G.), AG10491 (to P. G.), and AG11508 (to S. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Laboratory of Alzheimer Research, Dept. of Neurology and Neuroscience, Cornell University Medical College, 1300 York Ave., Rm. A569, New York, NY 10021. Fax: 212-746-8082.

(^1)
The abbreviations used are: AD, Alzheimer disease; Abeta, beta-amyloid peptide; beta-APP, beta-amyloid precursor protein; PKC, protein kinase C; sbeta-APP, soluble beta-APP; TGN, trans-Golgi network; PDBu, phorbol 12,13-dibutyrate; GTPS, guanosine 5`-3-O-(thio)triphosphate.

(^2)
The possible production of sbeta-APP was sought in experiments in which beta-APP amino-terminal antibody 22C11 was substituted for carboxyl-terminal antibody 369. However, no sbeta-APP was detected under standard conditions.


ACKNOWLEDGEMENTS

We thank Wieland Huttner for critical discussions and for a preprint of Ohashi and Huttner(1994) prior to its publication. We also thank Roberto Buccione and Alberto Luini for critical discussions and for sharing their unpublished observations. We thank Andrew J. Czernik for critical discussions, and Angus C. Nairn and Atsuko Horiuchi for generously supplying purified PKC.

Note Added in Proof-After this study was finished, additional evidence supporting the existence of a role for PKC in the regulation of TGN vesicle formation was described by Buccione et al. (R. Buccione, S. Bannykh, I. Santone, M. Baldassarre, F. Facchiano, Y. Bozzi, G. Di Tullio, A. Mironov, A. Luini, and M. De Matteis, submitted for publication) as well as by Simon et al. (Simon, J.-P., Ivanov, I. E., Shopsin, B., Hersh, D., Adesnik, M., and Sabatini, D. D. (1995) Cold Spring Harbor Symp. Quant. Biol.60, 222).


REFERENCES

  1. Arribas, J., and Massague, J. (1995) J. Cell Biol. 128,433-441 [Abstract]
  2. Bauerfeind, R., and Huttner, W. (1993) Curr. Opin. Cell Biol. 5,628-635 [Medline] [Order article via Infotrieve]
  3. Bosenberg, M., Pandiella, A., and Massague, J. (1993) J. Cell Biol. 122,95-101 [Abstract]
  4. Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernik, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,6003-6006 [Abstract]
  5. Caporaso, G., Gandy, S., Buxbaum, J., Ramabhadran, T., and Greengard, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,3055-3059 [Abstract]
  6. Caporaso, G., Takei, K., Gandy, S., Matteoli, M., Mundigl, O., Greengard, P., and de Camilli, P. (1994) J. Neurosci. 14,3122-3138 [Abstract]
  7. Citron, M., Vigo-Pelfrey, C., Teplow, D. B., Miller, C., Schenk, D., Johnston, J., Winblad, B., Venizelos, N., Lannfelt, L., and Selkoe, D. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,11993-11997 [Abstract/Free Full Text]
  8. da Cruz e Silva, O., Iverfeldt, K., Oltersdorf, T., Sinha, S., Lieberburg, I., Ramabhadran, T., Suzuki, T., Sisodia, S., Gandy, S., and Greengard, P. (1993) Neuroscience 57,873-877 [CrossRef][Medline] [Order article via Infotrieve]
  9. De Matteis, M. A., Santini, G., Kahn, R. A., Di Tullio, G., and Luini, A. (1993) Nature 364,818-821 [CrossRef][Medline] [Order article via Infotrieve]
  10. Felsenstein, K., Hunihan, L. W., and Roberts, S. B. (1994a) Nat. Genet. 6,251-255 [Medline] [Order article via Infotrieve]
  11. Felsenstein, K., Ingalls, K., Hunihan, L., and Roberts, S. (1994b) Neurosci. Lett. 174,173-176 [Medline] [Order article via Infotrieve]
  12. Glenner, G. G., and Wong, C. W. (1984) Biochem. Biophys. Res. Commun. 122,885-890
  13. House, C., and Kemp, B. (1987) Science 238,1726-1728 [Medline] [Order article via Infotrieve]
  14. Hung, A. Y., Haass, C., Nitsch, R. M., Qiu, W. Q., Citron, M., Wurtman, R. J., Growdon, J. H., and Selkoe, D. J. (1993) J. Biol. Chem. 268,22959-22962 [Abstract/Free Full Text]
  15. Kang, J., LeMaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G. H., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325,733-736 [CrossRef][Medline] [Order article via Infotrieve]
  16. L'Hernault, S. W., and Arduengo, P. M. (1992) J. Cell Biol. 119,55-68 [Abstract]
  17. Ohashi, M., and Huttner, W. B. (1994) J. Biol. Chem. 269,24897-24905 [Abstract/Free Full Text]
  18. Rothman, J. (1994) Nature 372,55-62 [CrossRef][Medline] [Order article via Infotrieve]
  19. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J.-F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A. R., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St. George-Hyslop, P. H. (1995) Nature 375, 754-760 [CrossRef][Medline] [Order article via Infotrieve]
  20. Tooze, S., and Huttner, W. (1992) Methods Enzymol. 219,81-93 [Medline] [Order article via Infotrieve]
  21. Woodgett, J., and Hunter, T. (1987) J. Biol. Chem. 262,4836-4843 [Abstract/Free Full Text]
  22. Xu, H., and Shields, D. (1993) J. Cell Biol. 122,1169-1184 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.